Valeant Pharmaceuticals (VRX.TO) Buy, Sell or…

Valeant Pharmaceuticals (VRX.TO)

0.00

-0.00 (0.00%)

39 watching

WAIT

Has had some problems and are facing the OCC and FCC. At this price, much of the negative news is out of the stock. Wait until you see a turn in the share price.

DON'T BUY

Not a fan. It will take a lot of things to happen for this company to fix itself.

DON'T BUY

Once problems occur, they tend to multiply.

DON'T BUY

Has some pretty major issues facing it. Being investigated by the OCC and FCC. Their core business has been quite disappointing.

DON'T BUY

Will drop lower. Selloff has started and is now accelerating. There is no support.

DON'T BUY

Has a lot of unhappy shareholders and are just waiting to sell their shares. Wait for the stock to turn around and put a good bottom in.

BUY

Thinks that the issues on the accounting side have been taking care of. Better transparency. Their antidepressant drug is selling well. Competition is heating up with their generic drugs. Looking for some upside over the next six months.

DON'T BUY

It looks quite cheap. Not sure if you can believe their numbers.

TOP PICK

$20/25 is an area where you should buy the stock for the long-term.

DON'T BUY

Sold their holdings because of lack of comfort with the clarity of their accounting and lacked confidence in their management. Under investigation.

WAIT

A wait and see stock. It will eventually rise. Earnings are coming out next week but is not expecting anything brilliant.

DON'T BUY

A high maintenance stock. Too many moving parts. Never quite know what is going on with it. Has nice technology.

DON'T BUY

Wouldn't touch the stock. Too much uncertainty, pipeline, management comments, OSC. Investigation, etc. for pharmaceuticals, look to names in the US.

DON'T BUY

Has a problem with their sustainable value of having a delivery mechanism without competition. Has had problems with corporate governance, accounting and regulatory issues.

DON'T BUY

Trades at a very low multiple because of problems over the last few years. Volatile.

Showing 451 to 465 of 714 entries

Wealthica The ultimate 360° Tracker Your financial life in one place, automatically

Most Recent Experts

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Keith Richards

ValueTrend Wealth Management

Joe Terranova

Virtus Investment Partners

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Rob Sechan, Managing Partner, New Edge Capital

New Edge Capital

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Summer Sale

Valeant Pharmaceuticals (VRX.TO)